Trial
NCT02847650
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Pfizer
Collaborators
—
Condition
Parkinson Disease
Intervention
Placebo
Why stopped
Study B7601011 was terminated on 29 Jan 2018 due to lack of efficacy in moderate/advanced Parkinson's disease.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-23